Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Weigao Group Medical Polymer Company Limited (1066.HK)
Weihai, CN
Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.44% | -3.45% | -2.33% | -33.99% | -39.46% | -33.07% | -40.11% | -70.88% | -80.40% | -25.50% | +1,820.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | -1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+2.3% Q4'25: +6.5% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-22.2% Q4'25: -26.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+8.7% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+13.8% ★ Q4'25: +9.9% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+7.1% ★ Q4'25: +9.9% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.2% ★ Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.18× ★ Q4'25: 1.34× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 10 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.88B
est: 1.70B (+10.4%)
|
2.46B
est: 2.13B (+15.8%)
|
3.18B
est: 2.65B (+20.1%)
|
3.69B
est: 3.19B (+15.7%)
|
4.61B
est: 3.71B (+24.3%)
|
5.28B
est: 4.19B (+26.0%)
|
5.92B
est: 7.21B (-18.0%)
|
6.73B
est: 7.38B (-8.8%)
|
6.29B
est: 9.00B (-30.1%)
|
8.81B
est: 9.38B (-6.1%)
|
10.36B
est: 11.62B (-10.8%)
|
11.62B
est: 13.27B (-12.4%)
|
13.15B
est: 16.36B (-19.6%)
|
13.62B
est: 16.83B (-19.1%)
|
13.23B
est: 12.06B (+9.7%)
|
13.09B
est: 13.32B (-1.8%)
|
13.39B
est: 13.54B (-1.2%)
|
14.69B
14.53B – 14.83B
+8.5% YoY
|
15.60B
15.00B – 17.07B
+6.2% YoY
|
16.26B
15.84B – 17.12B
+4.2% YoY
|
| EBITDA |
783.13M
est: 664.55M (+17.8%)
|
991.02M
est: 1.01B (-1.7%)
|
3.69B
est: 1.23B (+199.5%)
|
1.26B
est: 881.42M (+42.9%)
|
1.30B
est: 1.33B (-1.9%)
|
1.54B
est: 715.46M (+115.6%)
|
1.70B
est: 1.44B (+18.0%)
|
1.72B
est: 1.54B (+12.1%)
|
1.91B
est: 1.53B (+25.2%)
|
2.62B
est: 2.15B (+21.8%)
|
3.27B
est: 2.16B (+50.8%)
|
3.09B
est: 2.37B (+30.6%)
|
3.75B
est: 2.71B (+38.3%)
|
4.38B
est: 3.43B (+27.8%)
|
3.55B
est: 3.19B (+11.5%)
|
3.14B
est: 3.54B (-11.3%)
|
2.75B
est: 3.58B (-23.1%)
|
3.88B
3.84B – 3.92B
+8.5% YoY
|
4.12B
3.96B – 4.51B
+6.2% YoY
|
4.30B
4.19B – 4.53B
+4.2% YoY
|
| EBIT |
708.96M
est: 528.68M (+34.1%)
|
897.54M
est: 624.37M (+43.8%)
|
3.59B
est: 740.02M (+385.6%)
|
1.13B
est: 683.97M (+65.3%)
|
553.11M
est: 902.97M (-38.7%)
|
1.30B
est: 442.91M (+193.1%)
|
1.38B
est: 1.26B (+9.9%)
|
1.21B
est: 1.36B (-10.8%)
|
1.55B
est: 1.17B (+32.5%)
|
2.06B
est: 1.45B (+41.6%)
|
2.65B
est: 2.15B (+23.2%)
|
2.40B
est: 2.46B (-2.5%)
|
3.02B
est: 2.83B (+6.7%)
|
3.58B
est: 3.57B (+0.2%)
|
2.64B
est: 2.42B (+9.1%)
|
2.27B
est: 2.69B (-15.5%)
|
1.85B
est: 2.72B (-32.1%)
|
2.95B
2.92B – 2.98B
+8.5% YoY
|
3.13B
3.01B – 3.43B
+6.2% YoY
|
3.26B
3.18B – 3.44B
+4.2% YoY
|
| Net Income |
633.86M
est: 520.59M (+21.8%)
|
799.07M
est: 696.81M (+14.7%)
|
3.46B
est: 844.43M (+310.0%)
|
996.49M
est: 3.54B (-71.9%)
|
387.98M
est: 934.96M (-58.5%)
|
1.08B
est: 352.15M (+208.1%)
|
1.11B
est: 1.05B (+6.1%)
|
1.11B
est: 1.09B (+1.2%)
|
1.30B
est: 1.07B (+22.1%)
|
1.47B
est: 1.62B (-9.2%)
|
1.84B
est: 1.56B (+18.0%)
|
2.09B
est: 1.77B (+17.6%)
|
2.28B
est: 2.04B (+11.8%)
|
2.76B
est: 2.40B (+15.2%)
|
2.00B
est: 1.78B (+12.6%)
|
2.07B
est: 2.09B (-1.1%)
|
1.61B
est: 2.00B (-19.3%)
|
1.78B
1.71B – 1.85B
-11.0% YoY
|
1.78B
1.60B – 2.42B
-0.1% YoY
|
2.06B
1.87B – 2.26B
+16.1% YoY
|
| SGA |
502.26M
est: 370.48M (+35.6%)
|
763.51M
est: 548.63M (+39.2%)
|
919.22M
est: 806.81M (+13.9%)
|
1.09B
est: 905.08M (+20.1%)
|
1.48B
est: 1.02B (+44.6%)
|
1.74B
est: 1.34B (+30.4%)
|
1.94B
est: 1.71B (+13.6%)
|
2.57B
est: 1.93B (+33.1%)
|
2.34B
est: 2.18B (+7.6%)
|
3.37B
est: 2.23B (+50.9%)
|
3.77B
est: 3.59B (+4.9%)
|
3.66B
est: 3.64B (+0.5%)
|
3.77B
est: 4.17B (-9.6%)
|
3.54B
est: 5.27B (-32.8%)
|
3.83B
est: 3.38B (+13.4%)
|
3.63B
est: 3.75B (-3.3%)
|
3.83B
est: 3.79B (+1.1%)
|
4.12B
4.07B – 4.15B
+8.5% YoY
|
4.37B
4.20B – 4.78B
+6.2% YoY
|
4.55B
4.44B – 4.80B
+4.2% YoY
|
| EPS |
0.15
est: 0.14 (+9.7%)
|
0.19
est: 0.16 (+16.6%)
|
0.78
est: 0.22 (+246.9%)
|
0.22
est: 0.20 (+11.9%)
|
0.09
est: 0.17 (-46.6%)
|
0.24
est: 0.18 (+33.2%)
|
0.25
est: 0.32 (-21.5%)
|
0.25
est: 0.28 (-11.9%)
|
0.29
est: 0.39 (-24.7%)
|
0.33
est: 0.37 (-11.4%)
|
0.41
est: 0.48 (-14.6%)
|
0.46
est: 0.55 (-16.3%)
|
0.51
est: 0.67 (-23.7%)
|
0.61
est: 0.67 (-8.5%)
|
0.44
est: 0.39 (+11.5%)
|
0.46
est: 0.45 (+1.7%)
|
0.35
est: 0.44 (-20.0%)
|
0.39
0.38 – 0.41
-9.9% YoY
|
0.43
0.35 – 0.53
+8.8% YoY
|
0.45
0.41 – 0.50
+3.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Dividend Aristocrats UCITS ETF (Dist) EDVD.L | 1.62% | 2.82M | 0.55% |
| 2 | First Trust WCM Developing World Equity ETF WCME | 1.18% | 427.3K | 0.95% |
| 3 | iShares MSCI China Small-Cap ETF ECNS | 0.66% | 426.2K | 0.59% |
| 4 | First Trust Emerging Markets Small Cap AlphaDEX Fund FEMS | 0.42% | 1.07M | 0.80% |
| 5 | Amundi MSCI China Tech UCITS ETF EUR CC1.PA | 0.40% | 1.17M | 0.55% |
| 6 | Amundi MSCI China Tech UCITS ETF USD CC1U.L | 0.40% | 1.17M | 0.55% |
| 7 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.12% | 140.7K | 0.42% |
| 8 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.09% | 1.66M | 0.58% |
| 9 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.09% | 439.8K | 0.32% |
| 10 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.09% | 62.3K | 0.74% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Long | Executive Chairman of the Board & Compliance Officer | 3M | male |
| Rinan Cong | Chief Executive Officer & Executive Director | 2M | male |
| Daoming Wang | Executive Director | 774.8K | male |
| Junqiang Lu | Executive Director | 774.8K | male |
| Miu Ling Wong | Company Secretary | — | female |
| Xue Feng Wu | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1066.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
